In 2011, “Study on Qi She Pill against nerve root type cervical spondylosis” was approved by Shanghai Municipal Science and Technology Commission to be one of the cooperation projects of “Technological Innovation Action Plan” in biomedical field (Project Number: 11DZ1921100). This project was authorized by Shanghai Municipal Science and Technology Commission, and conducted by Shanghai Sundise Traditional Chinese Medicine Co., Ltd (“Sundise”) and 8 third-grade hospitals in Shanghai. This project will enroll more than 2400 subjects for the purpose of evaluating the long-term safety and effectiveness of Qi She Pill. It has a wide range of clinical significances.
In order to promote and accelerate the process of Qi She Pill revaluation study, the first “Investigators’ meeting of study on revaluation of Qi She Pill against nerve root type cervical spondylosis” was held by Sundise at Shanghai Park Hyatt Hotel on February 3rd 2012. The attendees include the leaders from Science and Education Department of Shanghai Municipal Health Bureau and Biological Medicine Department of Shanghai Municipal Science and Technology Commission, as well as all principal investigators of this project.
This meeting was hosted by Sundise Deputy General Manager Ms. Biquan Wang. Sundise General Manager Mr. Huashi Bian made an opening remark. The study protocol and project management were deeply discussed by investigators and related CRO in this meeting.
Mr. Kan Zhang, the division chief of Science and Education Department of Shanghai Municipal Health Bureau, made a summary speech for this meeting. He indicated that the cooperation projects supported by Shanghai Municipal Science and Technology Commission are the great innovation of scientific research cooperation mode in China. He hopes Sundise can well cooperate with each hospital, and actively carry out the Qi She Pill Revaluation study together. We should contribute ourselves to the standardization and modernization of traditional Chinese Medicine.